A novel approach to assess Lung Health

Functional Respiratory Imaging (FRI) is a imaging technology which enhances drug development and patient care by providing patient-specific parameters

A novel approach to assess Lung Health

Functional Respiratory Imaging (FRI) is a imaging technology which enhances drug development and patient care by providing patient-specific parameters

Patient-specific parameters

  • 3D visualization and quantification of patient’s airway and lung geometry on a regional, often lobar, level
  • Deposition characteristics of inhaled compounds

Patient-specific parameters

  • 3D visualization and quantification of patient’s airway and lung geometry on a regional, often lobar, level
  • Deposition characteristics of inhaled compounds

FRI benefits

Use in Clinical Trials

FRI reduces the cost and time required for screening most promising new respiratory drugs in early clinical phase

Use in Clinical Practice

FRI is sensitive and identifies more quickly inefficient therapies, improving patient care

FRI benefits

Use in Clinical Trials

FRI reduces the cost and time required for screening most promising new respiratory drugs in early clinical phase

Use in Clinical Practice

FRI is sensitive and identifies more quickly inefficient therapies, improving patient care

FLUIDDA’s technique and insights to the subject were outstanding. We were delighted with the science and collaboration we had with FLUIDDA.

Mark Milton – Edwards Global Dir. Respiratory, TEVA

FLUIDDA’s technology is an important tool which helps bridge data from in vitro and in vivo studies.

Dr. Paul M. Dorinsky – Head Global Respiratory Clinical Development, Cipla

FLUIDDA’s technique and insights to the subject were outstanding. We were delighted with the science and collaboration we had with FLUIDDA.

Mark Milton – Edwards Global Dir. Respiratory, TEVA

FLUIDDA’s technology is an important tool which helps bridge data from in vitro and in vivo studies.

Dr. Paul M. Dorinsky – Head Global Respiratory Clinical Development, Cipla

A thorough understanding of a pharmaceutical company’s target disease is imperative when they want to successfully develop and market their
Read More
We’ve said it before: the respiratory field is the most expensive one in the pharmaceutical world. The low sensitivity of
Read More
Cystic fibrosis (CF) is a devastating, chronic disease that affects over 100,000 people worldwide. The consequences patients need to bear
Read More
In the previous blogpost the complexity of delivering inhaled drugs into the lung was discussed. It was shown that functional
Read More